The PROTECT-V trial investigating UNIONs COVID-19 candidate receives Urgent Public Health Prioritization from the UK government
UNION therapeutics A/S (UNION) today announced that the National Institute for Health Research (NIHR) in the UK has granted Urgent Public Health (UPH) prioritization to the PROTECT-V trial – a platform study investigating UNION’s niclosamide-based treatment candidate for COVID-19 in kidney patients.
Clinical trials granted UPH prioritization by the NIHR are deemed critically important in the fight against COVID-19 and will thus receive infrastructure support allowing expedited recruitment for the study. NIHR is an entity under the Department of Health & Social Care of the UK government.
UPH prioritization will enable streamlined site set up across the UK, and facilitate rapid patient recruitment as a result of NIHR resource and clinical research network support being available.
The PROTECT-V trial is led by the Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge and involves researchers and patients from across the UK.
For more information visit: UNION Therapeutics
Published March 29 2021
Latest from CCTU
New approach to treating aggressive breast cancer by Cambridge researchers shows significant improvement in survival
Researchers at NIHR Cambridge Biomedical Research Centre have shown that a new treatment approach significantly improves survival rates for patients with…
Groundbreaking Cambridge research indicates immunosuppression may help treat Parkinson’s
A pioneering trial, led from Cambridge Biomedical Research Centre, has shown that…
AI power improves cataract test tool for babies
A device invented by an Addenbrooke's eye surgeon to detect cataract in babies is set to be further improved - thanks to artificial intelligence and a team…
